| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8830328 | Urology Practice | 2017 | 19 Pages |
Abstract
Risk stratification tools incorporating genomic analysis of prostate cancer have been developed which seek to improve the accuracy of initial predictions. Further study is warranted to define the additive clinical benefit associated with their use if implemented broadly.
Keywords
NCCN®CCPCCRBCRPSAPCAProstate specific antigenDecision support techniquesRadical prostatectomyGPSCancer of the Prostate Risk AssessmentProstate cancerBiochemical recurrencephosphatase and tensin homologfluorescence in situ hybridizationFishProstatic neoplasmsActive surveillanceGenomic Prostate ScoreprognosisCell cycle progressionPtenGenomicsCAPRA
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Michael S. Leapman, Peter R. Carroll,